Toronto-based Intellipharmaceutics is a pioneering company in the global pharmaceutical industry, having been established in 1998. A key aspect of Intellipharmaceutics' offerings is its proprietary Hypermatrix™ technology, which serves as a versatile and proven multidimensional controlled-release drug delivery platform. This innovation supports the development of a wide variety of pharmaceutical products, including those already on the market as well as new drug types. Intellipharmaceutics' pipeline comprises generic and new drugs spanning multiple therapeutic categories.